Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma

Cancers

Alexandra R. Lucas¹  Masmudur M. Rahman¹  Liqiang Zhang¹  Natalie Elliott¹  Jacquelyn Kilbourne²  Kenneth Lowe²  Juliane Daggett-Vondras²  John D. Christie³  Grant McFadden³  Nicole Appel³  Joseph N. Blattman³ 

[1] Biodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA;Department of Animal Care and Technologies, Arizona State University, Tempe, AZ 85287, USA;School of Life Sciences, Arizona State University, Tempe, AZ 85281, USA;

关键词: oncolytic viruses;    oncolytic myxoma virus;    armed oncolytic virus;    TNF superfamily;    oncolytic virus metastatic tumors;    LIGHT (TNFSF14);   

DOI  :  10.3390/cancers14020337

来源: DOAJ

【 摘 要 】

Cancers that metastasize to the lungs represent a major challenge in both basic and clinical cancer research. Oncolytic viruses are newly emerging options but successful delivery and choice of appropriate therapeutic armings are two critical issues. Using an immunocompetent murine K7M2-luc lung metastases model, the efficacy of MYXV armed with murine LIGHT (TNFSF14/CD258) expressed under virus-specific early/late promoter was tested in an advanced later-stage disease K7M2-luc model. Results in this model show that mLIGHT-armed MYXV, delivered systemically using ex vivo pre-loaded PBMCs as carrier cells, reduced tumor burden and increased median survival time. In vitro, when comparing direct infection of K7M2-luc cancer cells with free MYXV vs. PBMC-loaded virus, vMyx-mLIGHT/PBMCs also demonstrated greater cytotoxic capacity against the K7M2 cancer cell targets. In vivo, systemically delivered vMyx-mLIGHT/PBMCs increased viral reporter transgene expression levels both in the periphery and in lung tumors compared to unarmed MYXV, in a tumor- and transgene-dependent fashion. We conclude that vMyx-mLIGHT, especially when delivered using PBMC carrier cells, represents a new potential therapeutic strategy for solid cancers that metastasize to the lung.

【 授权许可】

Unknown